EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

@article{Giammarile2008EANMPG,
  title={EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy},
  author={Francesco Giammarile and Arturo Chiti and Michael Lassmann and Boudewijn T. Brans and Glenn D Flux},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2008},
  volume={35},
  pages={1039-1047},
  url={https://api.semanticscholar.org/CorpusID:6884201}
}
This guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.
View on Springer
ncbi.nlm.nih.gov
186 Citations
Highly Influential Citations
7
Background Citations
44
Methods Citations
19

186 Citations

I-131 Metaiodobenzylguanidine Therapy of Neuroectodermal Tumors

Characteristics of the radiopharmaceutical are defined, cautions during administration are mentioned and clinical applications of I-131 MIBG therapy of the neuroec- todermal tumors are discussed.

131I-MIBG Therapy

131I-MIBG is an analog of guanethidine which has been used for imaging a variety of neuroendocrine tumors (NETs) and is used mostly to treat neuroblastoma, pheochromocytoma/paraganglioma (PHEO/PGL), and carcinoid tumors.

Current Consensus on I-131 MIBG Therapy

Astatine-211-labeled meta-astatobenzylguanidine (At-211 MABG) has massive potential in patients with neuroendocrine tumors, which is an alternative method after more effective novel therapies are used such as radiolabeled somatostatin analogs and tyrosine kinase inhibitors in Patients with advanced carcinoid tumors and MTC.

I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.

This article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.

131 I-Meta-Iodobenzylguanidine Therapy for Pheochromocytoma/Paraganglioma and Neuroblastoma

Patients with malignant/metastatic pheochromocytoma/paraganglioma (PHEO/PG) benefit from 131I-meta-iodobenzylguanidine (131I-mIBG) treatment: symptomatic response is high, but complete response is low, whereas 5-year survival ranges between 45 and 85 %.

131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma

This review will briefly discuss the radiopharmaceutical modalities in patients with pheochromocytomas and paragangliomas (131I-MIBG and PRRT), which has received FDA approval and promising results have been reported.

I-MIBG SPECT/CT for Tumour Imaging

mIBG is an aralkylguanidine norepinephrine analogue that enters the neuroendocrine cells of postganglionic sympathetic neurons by an active uptake mechanism via the epinephrine transporter and is stored in the neurosecretory granule without being metabolized.

Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma.

A review of the developments and recent advances in radiopharmaceutical theranostics of PGLs concludes that peptide receptor radionuclide therapy, which uses radiolabelled somatostatin (SST) analogues, has been exploited as a superior substitute.

A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol.

The current study is the first multi-institutional prospective study of MIBG therapy and thereby will play a significant role in improving the patients' prognosis of refractory PPGLs.

Multifunctional Nanostructured Materials Applied in Controlled Radiopharmaceuticals Release

It can be concluded that the hybrid matrix [SBA-15/P(N-iPAAm)] can be considered a potential alternative material for the controlled release delivery of radio-pharmaceuticals.
...

28 References

A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).

A comprehensive list of prescribed and over-the-counter medicines that have the potential to inhibit uptake of MIBG has been compiled and it is hoped that this will help nuclear medicine physicians to avoid false negative results.

Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection

The ultimate impact of high-dose scans on neuroblastoma management, however, seems limited: in only one case did the TS findings, namely skeletal involvement not evidenced on corresponding DS, have an impact on clinical staging.

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.

This schedule of intensification of (131)I-mIBG therapy by dose escalation and radiosensitization with topotecan with a haemopoietic autograft is safe and practicable and should be tested for efficacy in a phase II clinical trial.

Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study

These protocols describe the methods employed for both the tracer study using131I-mIBG and the subsequent therapy and the amount predicted to deliver a predefined whole-body dose.

Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours

The observation in the present study of important inter-individual variability in the total body dose, with the possibility of high dose values, suggests the necessity of individual dosimetry when administering 131I-MIBG therapy, especially considering that generally more than one therapy is given to each patient.

Radiolabeled Adrenergic Neuron-Blocking Agents: Adrenomedullary Imaging with [131I] Iodobenzylguanidine

The tissue distributions of three radioiodinated neuron-blocking agents have been determined in dogs. Iodine-125-labeled meta- and para-iodobenzylguanidines show a striking affinity for, and…

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

Iodine-131 metaiodobenzylguanidine therapy is in general well tolerated, but its effectiveness needs improvement and whole-body dosimetry as part of treatment planning needs to be improved.

Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.

MIBG therapy was most effective in patients with slower-growing tumors for whom initial treatment doses were 200 mCi or more, and was used for staging the extent of neuroblastoma before therapy is started.

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.

This study has established an effective method of activity prescription that predicts subsequent toxicity, with the maximally tolerated dose being sufficient activity to deliver a whole-body-absorbed radiation dose of 2.5 Gy.

Second malignancies in children with neuroblastoma after combined treatment with 131I‐metaiodobenzylguanidine

131I‐metaiodobenzylguanidine (131I‐MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma.…